This is demonstrated in chronic myeloid leukaemia (CML) when acquired resistance to TKIs is often the result of a new mutation within the BCR-ABL1 fusion gene. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.